

Lyon, January 23, 2021
PRESS RELEASE

Eurofins Biomnis detects variants of SARS-CoV-2

Eurofins Biomnis, the European leader in specialised clinical pathology, committed more than ever to face the pandemic, received on January 22nd the authorisation from the French Authorities to use its kit to detect variants of SARS-CoV-2. After having reinforced its two technical platforms in Paris and Lyon to respond to the increasing demand for screening by RT-PCR, the laboratory is now in the unique position in France with the capacity to detect of SARS-CoV-2 variants by RT-PCR. This kit allows the detection of the N501Y and A570D mutations characteristic of the British variant VOC-202012/01 (B.1.1.7). Moreover, the N501Y mutation being common to the British, South African and Brazilian variants, it does not allow, alone, to distinguish one variant from the other. Eurofins Biomnis is now participating in the effort to map the circulation of the variants in France based on patients having tested positive for Covid-19.

Its responsiveness is based on the technical expertise of its staff and the other companies of the Eurofins Group. Some have developed their own in-house solutions as well as CE marked reagents and kits for the first-line RT-PCR test, all validated by the French National Reference Centre for Respiratory Infections Viruses (Pasteur Institute). They enable biologists and technicians to be independent of any one type of reagent or supplier and allow Eurofins Biomnis to pursue its public health mission to serve patients and healthcare professionals while limiting supply chain risks.

Eurofins Biomnis Press contact

Agence Wellcom
Gaëlle Ryouq, Héroïse Sintès
biomnis@wellcom.fr
+33 (0)1 46 34 60 60

wellcom



About Eurofins Biomnis

Eurofins Biomnis is the European leader in the field of specialised medical biology and performs more than 32,000 analyses per day on a panel of more than 2,500 tests, including specialised procedures for which it has all the necessary approvals. Founded in 1897 by Marcel Mérieux, Eurofins Biomnis remains the leading player in specialised medical pathology in France as a result of its continuous innovation and technological investments, particularly in the fields of women's pathologies, oncology and personalised medicine, as well as chromosomal and molecular genetics. Built on 120 years of expertise and innovation in medical pathology, Eurofins Biomnis, the European flagship laboratory of the Eurofins Group's Clinical Diagnostics Division, continues to pursue its international expansion. www.eurofins-biomnis.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.